Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Louise D. Johnson"'
Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones
Autor:
Alice C. Harnden, Owen A. Davis, Gary M. Box, Angela Hayes, Louise D. Johnson, Alan T. Henley, Alexis K. de Haven Brandon, Melanie Valenti, Kwai-Ming J. Cheung, Alfie Brennan, Rosemary Huckvale, Olivier A. Pierrat, Rachel Talbot, Michael D. Bright, Hafize Aysin Akpinar, Daniel S. J. Miller, Dalia Tarantino, Sharon Gowan, Selby de Klerk, Peter Craig McAndrew, Yann-Vaï Le Bihan, Mirco Meniconi, Rosemary Burke, Vladimir Kirkin, Rob L. M. van Montfort, Florence I. Raynaud, Olivia W. Rossanese, Benjamin R. Bellenie, Swen Hoelder
Publikováno v:
Journal of Medicinal Chemistry. 66:5892-5906
Autor:
Rosemary Huckvale, Alice C. Harnden, Kwai-Ming J. Cheung, Olivier A. Pierrat, Rachel Talbot, Gary M. Box, Alan T. Henley, Alexis K. de Haven Brandon, Albert E. Hallsworth, Michael D. Bright, Hafize Aysin Akpinar, Daniel S. J. Miller, Dalia Tarantino, Sharon Gowan, Angela Hayes, Emma A. Gunnell, Alfie Brennan, Owen A. Davis, Louise D. Johnson, Selby de Klerk, Craig McAndrew, Yann-Vaï Le Bihan, Mirco Meniconi, Rosemary Burke, Vladimir Kirkin, Rob L. M. van Montfort, Florence I. Raynaud, Olivia W. Rossanese, Benjamin R. Bellenie, Swen Hoelder
Publikováno v:
Journal of Medicinal Chemistry. 65:8191-8207
The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader
Autor:
Janet Shipley, Andrew D. Pearson, Torsten Pietsch, Khin Thway, Joanna L. Selfe, Florence I. Raynaud, Louise D. Johnson, Ruth R. Ruddle, Suzanne A. Eccles, Sharon Gowan, Alexis De Haven Brandon, Melanie Valenti, Ryan Bishop, Kathryn R. Taylor, Jane Renshaw
Supplementary Table & Figure Legends - PDF file 41K, Detailed captions for: Suppl Table S1. Immunohistochemical analysis indicates correlation between pAKT(Ser473),pERK1/2(Thr202/Tyr204) and pS6(Ser235/236) in primary tumours Fig S1. High level expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53c9f0ee11f97ffac3717cb5571e4679
https://doi.org/10.1158/1078-0432.22448514
https://doi.org/10.1158/1078-0432.22448514
Autor:
Janet Shipley, Andrew D. Pearson, Torsten Pietsch, Khin Thway, Joanna L. Selfe, Florence I. Raynaud, Louise D. Johnson, Ruth R. Ruddle, Suzanne A. Eccles, Sharon Gowan, Alexis De Haven Brandon, Melanie Valenti, Ryan Bishop, Kathryn R. Taylor, Jane Renshaw
Supplementary Methods - PDF file 44K, Method for the preparation and analysis of AZD8055, AZD6244 and BEZ235 by LC-MS/MS Drug-drug interaction assay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9364b3e24f067b196463b105995d4e03
https://doi.org/10.1158/1078-0432.22448517.v1
https://doi.org/10.1158/1078-0432.22448517.v1
Autor:
Janet Shipley, Andrew D. Pearson, Torsten Pietsch, Khin Thway, Joanna L. Selfe, Florence I. Raynaud, Louise D. Johnson, Ruth R. Ruddle, Suzanne A. Eccles, Sharon Gowan, Alexis De Haven Brandon, Melanie Valenti, Ryan Bishop, Kathryn R. Taylor, Jane Renshaw
Purpose: To provide rationale for using phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathway inhibitors to treat rhabdomyosarcomas, a major cause of pediatric and adolescent cancer deaths.Experimental Design: The pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1edec120d9d6bdb1a605751e4045ba03
https://doi.org/10.1158/1078-0432.c.6521415
https://doi.org/10.1158/1078-0432.c.6521415
Autor:
Janet Shipley, Andrew D. Pearson, Torsten Pietsch, Khin Thway, Joanna L. Selfe, Florence I. Raynaud, Louise D. Johnson, Ruth R. Ruddle, Suzanne A. Eccles, Sharon Gowan, Alexis De Haven Brandon, Melanie Valenti, Ryan Bishop, Kathryn R. Taylor, Jane Renshaw
Supplementary Table and Figures - PDF file 184K, Suppl Table S1: Immunohistochemical analysis indicates correlation between pAKT(Ser473),pERK1/2(Thr202/Tyr204) and pS6(Ser235/236) in primary tumours Fig S1. High level expression of p110delta in two o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aab04b89da9440c7b89b20b9d8e0f3c4
https://doi.org/10.1158/1078-0432.22448511
https://doi.org/10.1158/1078-0432.22448511
Autor:
Benjamin R, Bellenie, Kwai-Ming J, Cheung, Ana, Varela, Olivier A, Pierrat, Gavin W, Collie, Gary M, Box, Michael D, Bright, Sharon, Gowan, Angela, Hayes, Matthew J, Rodrigues, Kartika N, Shetty, Michael, Carter, Owen A, Davis, Alan T, Henley, Paolo, Innocenti, Louise D, Johnson, Manjuan, Liu, Selby, de Klerk, Yann-Vaï, Le Bihan, Matthew G, Lloyd, P Craig, McAndrew, Erald, Shehu, Rachel, Talbot, Hannah L, Woodward, Rosemary, Burke, Vladimir, Kirkin, Rob L M, van Montfort, Florence I, Raynaud, Olivia W, Rossanese, Swen, Hoelder
Publikováno v:
Journal of Medicinal Chemistry
Deregulation of the transcriptional repressor BCL6 enables tumorigenesis of germinal center B-cells, and hence BCL6 has been proposed as a therapeutic target for the treatment of diffuse large B-cell lymphoma (DLBCL). Herein we report the discovery o